Small-cap ($155 million market-cap) Compugen (CGEN) of Tel Aviv, Israel, is soaring this morning, its shares up $1.31, or 32%, at $5.39, after the company announced significant test results on a novel target for treatment of epithelial cancer. The target, CGEN-671, a kind of protein found on the surface of cells, was discovered using computer simulation and was then shown experimentally to be highly prevalent in epithelial tumors, also known as carcinomas, that lead to breast, colorectal, lung and other cancers. The protein may be a good target for various therapies, the company said.
No comments:
Post a Comment